We got an inside look at how the biotech Spark used mazes to develop a first-of-its-kind treatment for eye disease on the way to selling itself for $4.8 billion

The biotech Spark Therapeutics needed a way to measure improvements to a patient’s quality of life when testing a new treatment for a rare eye…

Read More We got an inside look at how the biotech Spark used mazes to develop a first-of-its-kind treatment for eye disease on the way to selling itself for $4.8 billion